Maria Ribadeneira

1.1k citations

27 papers · 839 indexed · h-index 14

Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism 6
Biological Psychiatry top 10%
Behavioral Neuroscience top 10%
Genetics top 10%
- Hemoglobinopathies and Related Disorders 7
Hematology top 10%
- Acute Myeloid Leukemia Research 2
Oncology
- Drug Transport and Resistance Mechanisms 5
Physiology
- Erythrocyte Function and Pathophysiology 5
Cellular and Molecular Neuroscience
- Neuroscience and Neuropharmacology Research 3
Pediatrics, Perinatology and Child Health
- Pharmacological Effects and Toxicity Studies 3
Molecular Biology
- Receptor Mechanisms and Signaling 3

Co-authors: Yu Li Jameson Forster Ajay Madan Patrick Koch Maciej Czerwiński Liang‐Shang Gan Kathleen Carroll Karl Zech
Cited by: Pharmacology Biological Psychiatry Behavioral Neuroscience
Journals: Nature (1 paper)Nature Communications (1 paper)Blood (4 papers)
Partner nations: United States Canada Germany

In The Last Decade

Maria Ribadeneira

26 papers receiving 810 citations

Peers

Countries citing papers authored by Maria Ribadeneira

Since Specialization

Citations

This map shows the geographic impact of Maria Ribadeneira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Ribadeneira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Ribadeneira more than expected).

Fields of papers citing papers by Maria Ribadeneira

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Ribadeneira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Ribadeneira. The network helps show where Maria Ribadeneira may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Maria Ribadeneira, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maria Ribadeneira Line = papers co-authored together Maria Ribadeneira links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease Blood Advances ·Santosh L. Saraf,Robert Hagar,Modupe Idowu,Ifeyinwa Osunkwo,Kimberly Cruz,Frans A. Kuypers,R. Clark Brown,James Geib,Maria Ribadeneira,Patricia Schroeder,Eric Wu,Sanjeev Forsyth,Patrick Kelly,Theodosia A. Kalfa,Marilyn J. Telen	2024	7
2	FT-4202, a selective pyruvate kinase R activator for sickle cell disease Experimental Hematology ·Anna Ericsson,David J. Richard,Erik Wilker,Jr David R Lancia,Shawn P. Fessler,Paul Troccolo,Xiaozhang Zheng,Angela V. Toms,Christopher J. Dinsmore,Lili Yao,Frans A. Kuypers,Sandra Larkin,D.J. Marcotte,Keertik Fulzele,Maria Ribadeneira,Sylvie M. Guichard,Gary R. Marshall	2024	1
3	Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease Journal of Pharmacology and Experimental Therapeutics ·Patricia Schroeder,Keertik Fulzele,Sanjeev Forsyth,Maria Ribadeneira,Sylvie M. Guichard,Erik Wilker,Cathleen Marshall,Adam Drake,Rose Fessler,Diamantis G. Konstantinidis,Katie Seu,Theodosia A. Kalfa	2022	28
4	Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial Clinical Pharmacology in Drug Development ·Sanjeev Forsyth,Patricia Schroeder,James Geib,Leela Vrishabhendra,Diamantis G. Konstantinidis,Kari LaSalvia,Maria Ribadeneira,Eric Wu,Patrick Kelly,Theodosia A. Kalfa	2022	23
5	FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease Blood ·R. Clark Brown,Kimberly Cruz,Theodosia A. Kalfa,Frans A. Kuypers,Santosh L. Saraf,Jeremie H. Estepp,Luke R. Smart,Punam Malik,Mark A. Lerman,Renae Mayer,Maria Ribadeneira,Sanjeev Forsyth,Patricia Schroeder,Eric Wu,Patrick Kelly,Marilyn J. Telen	2020	14
6	Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials Diabetes Obesity and Metabolism ·Carine Beysen,Patricia Schroeder,Eric Wu,Julie Brevard,Maria Ribadeneira,Wei Lu,Kiran Dole,Terry O’Reilly,Linda Morrow,Marcus Hompesch,Marc K. Hellerstein,Kelvin W. Li,L. E. B. Johansson,Patrick Kelly	2020	42
7	Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies Blood ·Manish R. Patel,Guillermo Garcia‐Manero,Ronald Paquette,Shira Dinner,William B. Donnellan,Michael R. Grunwald,Maria Ribadeneira,Patricia Schroeder,Julie Brevard,Lindsey Wilson,Jennifer Sweeney,Patrick Kelly,Jeffrey E. Lancet	2019	22
8	Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects Blood ·Theodosia A. Kalfa,Frans A. Kuypers,Marilyn J. Telen,Punam Malik,Diamantis G. Konstantinidis,Jeremy H. Estepp,Hyon J. Kim,Santosh L. Saraf,Lindsey Wilson,Maria Ribadeneira,Sanjeev Forsyth,Patricia Schroeder,Adam Drake,Olga Polyanskaya,Patrick Kelly,Lukasz Biernat	2019	8
9	KCNQ channel openers reverse depressive symptoms via an active resilience mechanism Nature ·Allyson K. Friedman,Barbara Juarez,Stacy M. Ku,Hongxing Zhang,Rhodora C. Calizo,Jessica J. Walsh,Dipesh Chaudhury,Song Zhang,Angel Hawkins,David Dietz,James W. Murrough,Maria Ribadeneira,Erik H.F. Wong,Ming‐Hu Han,Rachael L. Neve	2016	35
10	KCNQ channel openers reverse depressive symptoms via an active resilience mechanism Nature Communications ·Allyson K. Friedman,Barbara Juarez,Stacy M. Ku,Hongxing Zhang,Rhodora C. Calizo,Jessica J. Walsh,Dipesh Chaudhury,Song Zhang,Angel Hawkins,David Dietz,James W. Murrough,Maria Ribadeneira,Erik H.F. Wong,Rachael L. Neve,Ming-Hu Han	2016	118
11	Concomitant administration of sGC stimulators with common classes of anti-hypertensive agents results in increased efficacy in spontaneously hypertensive rats BMC Pharmacology and Toxicology ·Peter Germano,Jenny Tobin,Robert D Jefferson,Courtney Shea,Adaline C. Smith,G-Yoon Jamie Im,James E. Sheppeck,James Wakefield,Kristie Sykes,Maria Ribadeneira,Samuel Rivers,Jaime L. Masferrer	2015	2
12	A strategy to reduce biliary clearance in early drug discovery Journal of Pharmacological and Toxicological Methods ·Nathalie Rioux,Édith Bellavance,Hugo Poirier,Mariève Dupuis,Michel Garneau,Maria Ribadeneira,Jianmin Duan	2013	1
13	A membrane vesicle-based assay to enable prediction of human biliary excretion Xenobiotica ·Federico Colombo,Hugo Poirier,Nathalie Rioux,Maria Arias Montecillo,Jianmin Duan,Maria Ribadeneira	2013	7
14	A simplified approach to predict CYP3A-mediated drug–drug interactions at early drug discovery: validation with clinical data Xenobiotica ·Nathalie Rioux,Joëlle Batonga,Federico Colombo,Jonathan Massé,Christine Zouki,Maria Ribadeneira,Jianmin Duan,Richard C. Bethell	2012	4
15	A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA_A receptor modulator – an in vitro and in vivo comparison British Journal of Clinical Pharmacology ·Diansong Zhou,Maria Sunzel,Maria Ribadeneira,Mark A. Smith,Dhaval Desai,Lin Jian-rong,Scott Grimm	2011	10
16	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1′ group for the β-amino hydroxamic acid derived TACE inhibitors Bioorganic & Medicinal Chemistry Letters ·Xiaotao Chen,Bahman Ghavimi,Ronald L. Corbett,Chu‐Biao Xue,Rui‐Qin Liu,Maryanne Covington,Mingxin Qian,Krishna Vaddi,David D. Christ,Karl D. Hartman,Maria Ribadeneira,James M. Trzăskos,Robert Newton,Carl P. Decicco,James J.‐W. Duan	2007	13
17	Synthesis and structure–activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors Bioorganic & Medicinal Chemistry Letters ·Chu‐Biao Xue,Xiaotao Chen,Xiaohua He,John Roderick,Ronald L. Corbett,Bahman Ghavimi,Rui‐Qin Liu,Maryanne Covington,Mingxin Qian,Maria Ribadeneira,Krishna Vaddi,James M. Trzăskos,Robert Newton,James J.‐W. Duan,Carl P. Decicco	2004	27
18	Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization Bioorganic & Medicinal Chemistry Letters ·Chu‐Biao Xue,Xiaohua He,John Roderick,Ronald L. Corbett,James J.‐W. Duan,Rui‐Qin Liu,Maryanne Covington,Mingxin Qian,Maria Ribadeneira,Krishna Vaddi,David D. Christ,Robert Newton,James M. Trzăskos,Ronald L. Magolda,Ruth R. Wexler,Carl P. Decicco	2003	26
19	Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes Drug Metabolism and Disposition ·Ajay Madan,Richard Graham,Kathleen Carroll,Daniel R. Mudra,L. Alayne Burton,Linda A. Krueger,April Downey,Maciej Czerwiński,Jameson Forster,Maria Ribadeneira,Liang‐Shang Gan,Edward L. LeCluyse,Karl Zech,Philmore Robertson,Patrick Koch,Lida Antonian,Greg Wagner,Yu Li,Andrew Parkinson	2003	276
20	Effects of Structural Modifications on the Intestinal Permeability of Angiotensin II Receptor Antagonists and the Correlation of In Vitro, In Situ, and In Vivo Absorption Pharmaceutical Research ·Maria Ribadeneira,Bruce J. Aungst,Charles J. Eyermann,Shiew‐Mei Huang	1996	29

About Maria Ribadeneira

Maria Ribadeneira is a scholar working on Genetics, Pharmacology and Hematology, having authored 27 papers that have together received 839 indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (7 papers), Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (5 papers), Erythrocyte Function and Pathophysiology (5 papers), Neuroscience and Neuropharmacology Research (3 papers), Pharmacological Effects and Toxicity Studies (3 papers), Receptor Mechanisms and Signaling (3 papers) and Acute Myeloid Leukemia Research (2 papers). The work is most often cited by research in Pharmacology (232 citations), Biological Psychiatry (40 citations) and Behavioral Neuroscience (49 citations). Maria Ribadeneira has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Yu Li, Jameson Forster, Ajay Madan, Patrick Koch, Maciej Czerwiński, Liang‐Shang Gan, Kathleen Carroll, Karl Zech, Philmore Robertson and Lida Antonian. Their work appears in journals such as Nature, Nature Communications and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact